The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells

Neuroscience

Volumn 259, Issue , 2014, Pages 113-125

  Pevida, M ^a   Lastra, A ^a   Meana, Á ^b   Hidalgo, A ^a   Baamonde, A ^a   Menéndez, Luis ^a  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Bone cancer induced pain; CCL5; CCR1; Hyperalgesia; J113863; Mouse

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; J113863; RANTES; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE INJURY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; FIBROSARCOMA; HYPERALGESIA; INOCULATION; MALE; MECHANICAL ALLODYNIA; MECHANICAL HYPERALGESIA; MELANOMA CELL; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINAL CORD; THERMAL HYPERALGESIA; TUMOR CELL;

ANALYSIS OF VARIANCE; ANOVA; BONE CANCER-INDUCED PAIN; C-C CHEMOKINE RECEPTOR TYPE 1; C-C CHEMOKINE RECEPTOR TYPE 5; CCL2; CCL5; CCR1; CCR5; CHEMOKINE (C-C MOTIF) LIGAND 2; CHEMOKINE (C-C MOTIF) LIGAND 5; D-ALA-PEPTIDE T-AMIDE; DAPTA; DMEM; DORSAL ROOT GANGLIA; DRG; DULBECCO'S MODIFIED EAGLE'S MEDIUM; EDTA; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHYLENEDIAMINETETRAACETIC ACID; FCS; FETAL CALF SERUM; HYPERALGESIA; J113863; MACROPHAGE INHIBITORY PROTEIN-1Α; MIP-1Α; MOUSE; PBS; PHOSPHATE-BUFFERED SALINE; RANTES; REGULATED ON ACTIVATION NORMAL T CELL EXPRESSED AND SECRETED; TRANSIENT RECEPTOR POTENTIAL VANILLOID 1; TRPV1;

ANALYSIS OF VARIANCE; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL5; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPERALGESIA; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PAIN MEASUREMENT; PAIN THRESHOLD; PEPTIDE T; RECEPTORS, CCR1; XANTHENES;

EID: 84891354041     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.11.055     Document Type: Article

References (63)

1. Abbadie C., Bhangoo S., De Koninck Y., Malcangio M., Melik-Parsadaniantz S., White F.A. Chemokines and pain mechanisms. Brain Res Rev 2009, 60:125-134.
2. Ahn D.K., Lee K.R., Lee H.J., Kim S.K., Choi H.S., Lim E.J., Park J.S. Intracisternal administration of chemokines facilitated formalin-induced behavioral responses in the orofacial area of freely moving rats. Brain Res Bull 2005, 66:50-58.
3. Arms L., Girard B.M., Malley S.E., Vizzard M.A. Expression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammation. Am J Physiol Renal Physiol 2013, 305:F111-F122.
4. Baamonde A., Lastra A., Juárez L., García-Suárez O., Meana A., Hidalgo A., Menéndez L. Endogenous beta-endorphin induces thermal analgesia at the initial stages of a murine osteosarcoma. Peptides 2006, 27:2778-2785.
5. Baamonde A., Curto-Reyes V., Juárez L., Meana A., Hidalgo A., Menéndez L. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci 2007, 81:673-682.
6. Benamar K., Geller E.B., Adler M.W. Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats. Eur J Pharmacol 2008, 592:93-95.
7. Bhangoo S., Ren D., Miller R.J., Henry K.J., Lineswala J., Hamdouchi C., Li B., Monahan P.E., Chan D.M., Ripsch M.S., White F.A. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain 2007, 3:38.
8. Blanchet X., Langer M., Weber C., Koenen R.R., von Hundelshausen P. Touch of chemokines. Front Immunol 2012, 3:175.
9. Bolin L.M., Murray R., Lukacs N.W., Strieter R.M., Kunkel S.L., Schall T.J., Bacon K.B. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 1998, 81:49-57.
10. Cambien B., Richard-Fiardo P., Karimdjee B.F., Martini V., Ferrua B., Pitard B., Schmid-Antomarchi H., Schmid-Alliana A. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One 2011, 6:e28842.
11. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
12. Cheng J.-F., Jack R. CCR1 antagonists. Mol Divers 2008, 12:17-23.
13. Curto-Reyes V., Juárez L., García-Pérez E., Fresno M.F., Hidalgo A., Menéndez L., Baamonde A. Local loperamide inhibits thermal hyperalgesia but not mechanical allodynia induced by intratibial inoculation of melanoma cells in mice. Cell Mol Neurobiol 2008, 28:981-990.
14. Curto-Reyes V., Llames S., Hidalgo A., Menéndez L., Baamonde A. Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 2010, 160:561-573.
15. Dairaghi D.J., Oyajobi B.O., Gupta A., McCluskey B., Miao S., Powers J.P., Seitz L.C., Wang Y., Zeng Y., Zhang P., Schall T.J., Jaen J.C. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012, 120:1449-1457.
16. Di Prisco S., Summa M., Chellakudam V., Rossi P.I., Pittaluga A. RANTES-mediated control of excitatory amino acid release in mouse spinal cord. J Neurochem 2012, 121:428-437.
17. Eijkelkamp N., Heijnen C.J., Willemen H.L., Deumens R., Joosten E.A., Kleibeuker W., den Hartog I.J., van Velthoven C.T., Nijboer C., Nassar M.A., Dorn G.W., Wood J.N., Kavelaars A. GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain. J Neurosci 2010, 30:2138-2149.
18. Gladue R.P., Brown M.F., Zwillich S.H. CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem 2010, 10:1268-1277.
19. Gonzalez-Rodriguez S., Llames S., Hidalgo A., Baamonde A., Menéndez L. Potentiation of acute morphine-induced analgesia measured by a thermal test in bone cancer-bearing mice. Fundam Clin Pharmacol 2012, 26:363-372.
20. Gosselin R.D., Dansereau M.A., Pohl M., Kitabgi P., Beaudet N., Sarret P., Mélik Parsadaniantz S. Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem 2008, 15:2866-2875.
21. Hang L.H., Shao D.H., Chen Z., Chen Y.F., Shu W.W., Zhao Z.G. Involvement of spinal CC chemokine ligand 5 in the development of bone cancer pain in rats. Basic Clin Pharmacol Toxicol 2013, 113:325-328.
22. Hu J.H., Zheng X.Y., Yang J.P., Wang L.N., Ji F.H. Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in rats. Neurosci Lett 2012, 517:60-63.
23. Hu J.H., Yang J.P., Liu L., Li C.F., Wang L.N., Ji F.H., Cheng H. Involvement of CX3CR1 in one cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res 2012, 1465:1-9.
24. Hu J.H., Wu M.Y., Tao M., Yang J.P. Changes in protein expression and distribution of spinal CCR2 in a rat model of bone cancer pain. Brain Res 2013, 1509:1-7.
25. Imai S., Ikegami D., Yamashita A., Shimizu T., Narita M., Niikura K., Furuya M., Kobayashi Y., Miyashita K., Okutsu D., Kato A., Nakamura A., Araki A., Omi K., Nakamura M., James Okano H., Okano H., Ando T., Takeshima H., Ushijima T., Kuzumaki N., Suzuki T., Narita M. Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic pain. Brain 2013, 136:828-843.
26. Jones T.B., Hart R.P., Popovich P.G. Molecular control of physiological and pathological T-cell recruitment after mouse spinal cord injury. J Neurosci 2005, 25:6576-6583.
27. Khasabova I.A., Stucky C.L., Harding-Rose C., Eikmeier L., Beitz A.J., Coicou L.G., Hanson A.E., Simone D.A., Seybold V.S. Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci 2007, 27:10289-10298.
28. Kiguchi N., Kobayashi Y., Maeda T., Saika F., Kishioka S. CC-chemokine MIP-1α in the spinal cord contributes to nerve injury-induced neuropathic pain. Neurosci Lett 2010, 484:17-21.
29. Kiguchi N., Maeda T., Kobayashi Y., Fukazawa Y., Kishioka S. Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 2010, 149:305-315.
30. Kiguchi N., Kobayashi Y., Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 2012, 12:55-61.
31. Kim D., You B., Lim H., Lee S.J. Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. Mol Pain 2011, 7:74.
32. Knerlich-Lukoschus F., Noack M., von der Ropp-Brenner B., Lucius R., Mehdorn H.M., Held-Feindt J. Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J Neurotrauma 2011, 28:619-634.
33. Knerlich-Lukoschus F., von der Ropp-Brenner B., Lucius R., Mehdorn H.M., Held-Feindt J. Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J Neurosurg Spine 2011, 14:583-597.
34. Liou J.T., Yuan H.B., Mao C.C., Lai Y.S., Day Y.J. Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model. Pain 2012, 153:1283-1291.
35. Liou J.T., Mao C.C., Ching-Wah Sum D., Liu F.C., Lai Y.S., Li J.C., Day Y.J. Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model. J Pain 2013, 14:24-35.
36. Menéndez L., Lastra A., Hidalgo A., Baamonde A. Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice. J Neurosci Methods 2002, 113:91-97.
37. Menéndez L., Lastra A., Fresno M.F., Llames S., Meana A., Hidalgo A., Baamonde A. Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res 2003, 969:102-109.
38. Menéndez L., Lastra A., Meana A., Hidalgo A., Baamonde A. Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav 2005, 81:114-121.
39. Menéndez L., Juárez L., García E., García-Suárez O., Hidalgo A., Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006, 393:70-73.
40. Milligan E.D., Zapata V., Chacur M., Schoeniger D., Biedenkapp J., O'Connor K.A., Verge G.M., Chapman G., Green P., Foster A.C., Naeve G.S., Maier S.F., Watkins L.R. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 2004, 20:2294-2302.
41. Naya A., Sagara Y., Ohwaki K., Saeki T., Ichikawa D., Iwasawa Y., Noguchi K., Ohtake N. Design, synthesis, and discovery of a novel CCR1 antagonist. J Med Chem 2001, 44:1429-1435.
42. Oh S.B., Tran P.B., Gillard S.E., Hurley R.W., Hammond D.L., Miller R.J. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001, 21:5027-5035.
43. Old E.A., Malcangio M. Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. Curr Opin Pharmacol 2012, 12:67-73.
44. Pevida M., González-Rodríguez S., Lastra A., Hidalgo A., Menéndez L., Baamonde A. CCL2 released at tumoral level contributes to the hyperalgesia evoked by intratibial inoculation of NCTC 2472 but not B16-F10 cells in mice. N-S Arch Pharmacol 2012, 385:1053-1061.
45. Pevida M., Lastra A., Hidalgo A., Baamonde A., Menéndez L. Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. Brain Res Bull 2013, 95:21-27.
46. Rajan A.J., Asensio V.C., Campbell I.L., Brosnan C.F. Experimental autoimmune encephalomyelitis on the SJL mouse: effect of gamma delta T cell depletion on chemokine and chemokine receptor expression in the central nervous system. J Immunol 2000, 164:2120-2130.
47. Réaux-Le Goazigo A., Van Steenwinckel J., Rostène W., Mélik-Parsadaniantz S. Current status of chemokines in the adult CNS. Prog Neurobiol 2013, 104:67-92.
48. Rosi S., Pert C.B., Ruff M.R., McGann-Gramling K., Wenk G.L. Chemokine receptor antagonist d-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience 2005, 134:671-676.
49. Saeki T., Naya A. CCR1 chemokine receptor antagonist. Curr Pharm Des 2003, 9:1201-1208.
50. Sarau H.M., Rush J.A., Foley J.J., Brawner M.E., Schmidt D.B., White J.R., Barnette M.S. Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function. J Pharmacol Exp Ther 1997, 283:411-418.
51. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999, 19:10886-10897.
52. Soria G., Lebel-Haziv Y., Ehrlich M., Meshel T., Suez A., Avezov E., Rozenberg P., Ben-Baruch A. Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans. Neoplasia 2012, 14:1-19.
53. Spiekstra S.W., Breetveld M., Rustemeyer T., Scheper R.J., Gibbs S. Wound-healing factors secreted by epidermal keratinocytes and dermal fibroblasts in skin substitutes. Wound Repair Regen 2007, 15:708-717.
54. Staniland A.A., Clark A.K., Wodarski R., Sasso O., Maione F., D'Acquisto F., Malcangio M. Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 2010, 114:1143-1157.
55. Sul O.J., Ke K., Kim W.K., Kim S.H., Lee S.C., Kim H.J., Kim S.Y., Suh J.H., Choi H.S. Absence of MCP-1 leads to elevated bone mass via impaired actin ring formation. J Cell Physiol 2012, 227:1619-1627.
56. Sun S., Cao H., Han M., Li T.T., Pan H.L., Zhao Z.Q., Zhang Y.Q. New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis. Pain 2007, 129:64-75.
57. Thacker M.A., Clark A.K., Bishop T., Grist J., Yip P.K., Moon L.D., Thompson S.W., Marchand F., McMahon S.B. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 2009, 13:263-272.
58. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., Pozzi S., Breitkreutz I., Kiziltepe T., Yasui H., Ocio E.M., Shiraishi N., Jin J., Okawa Y., Ikeda H., Mukherjee S., Vaghela N., Cirstea D., Ladetto M., Boccadoro M., Anderson K.C. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110:3744-3752.
59. White F.A., Miller R.J. Insights into the regulation of chemokine receptors by molecular signaling pathways: functional roles in neuropathic pain. Brain Behav Immun 2010, 24:859-865.
60. Wintges K., Beil F.T., Albers J., Jeschke A., Schweizer M., Claass B., Tiegs G., Amling M., Schinke T. Impaired bone formation and increased osteoclastogenesis in mice lacking chemokine (C-C motif) ligand 5 (CCL5). J Bone Miner Res 2013, 28:2070-2080.
61. Wu A.C., Morrison N.A., Kelly W.L., Forwood M.R. MCP-1 expression is specifically regulated during activation of skeletal repair and remodeling. Calcif Tissue Int 2013, 92:566-575.
62. Yu X., Huang Y., Collin-Osdoby P., Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004, 19:2065-2077.
63. Zhang N., Inan S., Cowan A., Sun R., Wang J.M., Rogers T.J., Caterina M., Oppenheim J.J. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A 2005, 102:4536-4541. Erratum in: Proc Natl Acad Sci U S A (2005) 102: 7050.